← All trials
NCT05318521
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Oct 19, 2022
- First posted
- Apr 8, 2022
- Last posted
- Apr 14, 2022
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Overseas Pharmaceuticals, Ltd.Lead sponsor
- Palm Beach Research CenterOverall official - principal investigator
- Virginia Contract Research Organization Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.